HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Sarcoma treatments require novel targets due to frequent recurrence.
• High-mobility group AT-hook 1 (HMGA1) is implicated in cancer progression.

Purpose of the Study:

• Investigate HMGA1's role in liposarcoma subtypes.
• Evaluate trabectedin's efficacy and mechanisms in liposarcoma.
• Explore combination therapies for drug-resistant liposarcoma.

Main Methods:

• Immunohistochemistry and RT-PCR on 68 liposarcoma specimens.
• Loss- and gain-of-function experiments in liposarcoma cell lines.
• In vitro and in vivo trabectedin treatment studies.
• NF-kB pathway analysis in sensitive and resistant liposarcoma cells.

Main Results:

• HMGA1 is highly expressed in myxoid and dedifferentiated liposarcoma.
• HMGA1 depletion/overexpression affects proliferation, motility, invasion, and drug resistance.
• Trabectedin downregulates HMGA1, E2F1, vimentin, and ZEB1 in liposarcoma.
• Trabectedin inhibits NF-kB in sensitive cells; NF-kB inhibition re-sensitizes resistant cells.

Conclusions:

• HMGA1 is a key oncogenic factor in liposarcoma progression and chemoresistance.
• Trabectedin targets the HMGA1/E2F1 axis, reducing mesenchymal markers.
• Combining NF-kB inhibitors with trabectedin is a promising strategy for resistant liposarcoma.